EMA launches new patient-reported suspected side effects web site
European citizens now can obtain information on suspected side effects, also known as suspected adverse drug reactions, of an additional 1,700 active substances contained in medicines approved in the European Union (E.U.) through a newly launched web site maintained by the EMA.
The web site launched in 2012 previously only contained information on suspected side effects reported with centrally authorized medicines. Its expansion now also allows the public to access the relevant information for medicines approved by national authorities in the E.U.
Suspected side effects are reported by patients, consumers and healthcare professionals. These reports are suspected but not necessarily established side effects. They may not be related to or caused by the medicine.
National medicines regulatory authorities or pharmaceutical companies that hold the marketing authorization for the medicine concerned are obliged to transmit these reports electronically to EudraVigilance, the European database of suspected side effects reported with medicines authorized in the European Economic Area (EEA). The information made available through the public web site comes directly from EudraVigilance.
Spontaneous reports of suspected side effects provide regulatory authorities with important information which is used to monitor the safety of a medicine. Throughout a medicine’s lifecycle, regulatory authorities analyze all reports together with all other available information on the medicines, to make sure that their benefits remain greater than their risks and to optimise their safe and effective use. Each report available on the public web site pulls together the total number of individual suspected side effects reports submitted to EudraVigilance. These aggregated data can be viewed by age group, sex, type of suspected side effect and outcome.
The EMA has published a leaflet in all official E.U. languages to encourage patients to report side effects. These reports help to gather more information on medicines on the market. In a real-life setting, where a larger and more diverse group of patients use the medicines, less common side effects may be observed.
Therefore, the European pharmacovigilance legislation has introduced the possibility for patients to report side effects directly to the authorities in all E.U. member states. The leaflet explains how patients can report side effects and includes contact details for all member states.
After the legislation entered into force in July 2012, the number of side effects reported directly from patients to national regulatory authorities or pharmaceutical companies within the EEA has increased significantly. In the second year of operation of the legislation, EudraVigilance received 35,600 patient reports compared to 21,600 in the year preceding the legislation. This is in addition to reports received from healthcare professionals.
The figure of 1,700 active substances represents a major subset of all active substances contained in nationally authorized medicines in the E.U. Roll-out of public access to suspected side effects related to all medicines available in the E.U. will occur gradually over the next few years.